Antiviral Drugs - LATAM

LATAM

Revenue in the Antiviral Drugs market is projected to reach US$1.83bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 0.00%, resulting in a market volume of US$1.83bn by 2028.
In global comparison, most revenue will be generated in the United States (US$30,640.00m in 2024).

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs as it is in the nature of viruses to mutate and thus to increase their tolerance to drugs. Growing revenues generated by drugs with active patents and the counteracting decline in the case of other drugs which face competition result in stagnant growth.

The largest area in this market is HIV. In parts of the world, antiviral drugs have succeeded in keeping HIV a chronic condition without its progressing to AIDS. For hepatitis C, the number of new patients is shrinking in the U.S. and in Europe. Due to the COVID-19 pandemic, fewer new patients decided to seek medical treatment, leading to a certain decline in the revenue of HIV drugs.

Clinical testing and emergency approvals of treatments for COVID-19 have led to an increase in revenue. After a considerable growth in 2022, the revenues are expected to remain at a high level.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.